➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
AstraZeneca
McKesson
Moodys
Dow

Last Updated: January 21, 2021

DrugPatentWatch Database Preview

zioptan Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Zioptan patents expire, and what generic alternatives are available?

Zioptan is a drug marketed by Akorn and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-three patent family members in thirty-one countries.

The generic ingredient in ZIOPTAN is tafluprost. There are three drug master file entries for this compound. Additional details are available on the tafluprost profile page.

US ANDA Litigation and Generic Entry Outlook for Zioptan

A generic version of zioptan was approved as tafluprost by MICRO LABS on August 19th, 2019.

  Start Trial

Paragraph IV (Patent) Challenges for ZIOPTAN
Tradename Dosage Ingredient NDA Submissiondate
ZIOPTAN SOLUTION/DROPS;OPHTHALMIC tafluprost 202514 2016-02-10

US Patents and Regulatory Information for zioptan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akorn ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514-001 Feb 10, 2012 AT RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Akorn ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514-001 Feb 10, 2012 AT RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for zioptan

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0850926 CA 2008 00041 Denmark   Start Trial
0850926 91943 Luxembourg   Start Trial 91943, EXPIRES: 20221222
0850926 SPC013/2011 Ireland   Start Trial SPC013/2011: 20110808, EXPIRES: 20221221
0850926 300407 Netherlands   Start Trial 300407, 20171222, EXPIRES: 20221221
0850926 339 Finland   Start Trial
0850926 SPC/GB09/005 United Kingdom   Start Trial PRODUCT NAME: TAFLUPROST OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: DK 43230 20080430; UK PL 16058/0011-0001 20081017
0850926 11C0020 France   Start Trial PRODUCT NAME: TAFLUPROST; REGISTRATION NO/DATE IN FRANCE: CIS:6 000 728 O DU 20110328; REGISTRATION NO/DATE AT EEC: 43230 DU 20080430
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Johnson and Johnson
Medtronic
Dow
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.